KANGSTEM BIOTECH CO., LTD. Q3 operating loss of KRW 5.3 billion on KRW 0.6 billion in sales
Operating profit · 3 months
KRW -5.3 billion
Key facts
- Revenue (3 months)
- KRW 612.8 million
- Net income (3 months)
- KRW -5.2 billion
- Period
- Q3 (cumulative 2026.01.01 ~ 2026.09.30)
- Revenue (prior-year 3 months)
- KRW 485.1 million
- Revenue (year to date)
- KRW 2.1 billion
- Operating profit (prior-year 3 months)
- KRW -4.2 billion
- Operating profit (year to date)
- KRW -16.0 billion
- Net income (prior-year 3 months)
- KRW -4.5 billion
- Net income (year to date)
- KRW -16.0 billion
Commentary
AI commentary · Not investment advice
What happened
Kangstem Biotech reported its consolidated results for the 3rd quarter of 2026. Sales for the latest 3 months were KRW 612.8 million. That is up 26.3% from KRW 485.1 million a year earlier. It is down 4.5% from the previous quarter. Cumulative sales this year are KRW 2.06 billion.
In the company's terms
Operating profit (profit from the core business) for the latest 3 months was a loss of KRW 5.33 billion. A year earlier, the same period showed a loss of KRW 4.19 billion. The cumulative operating loss this year is KRW 15.96 billion.
What changes for shareholders
Net income (the final profit after taxes and all other items) for the latest 3 months was a loss of KRW 5.18 billion. A year earlier, it was a loss of KRW 4.46 billion. The cumulative net loss this year is KRW 15.99 billion.
Comments
No comments yet
Comments from shareholders will appear here.
Ad
Verify your holdings and catch the next disclosure
Verify the stocks you hold and get new disclosures as app alerts.

App design sample
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist
K